



Scientist/ Associate Scientist, Cancer Immunotherapy (Stealth)
Job code 413AW

Description

Fate Therapeutics is seeking a highly motivated individual with expertise in cancer immunology and allogeneic adoptive cell transfer biology or related fields to join a multidisciplinary team dedicated to the discovery of novel cellular therapeutics for the treatment of cancer. The candidate must have extensive experience with mammalian cell culture and a thorough understanding of NK or T cell biology. Additionally, the ideal candidate possesses demonstrated knowledge of allogeneic models of rejection including MLR, graft-vs-host disease, transplant immunology, or related fields. Experience with current molecular biology techniques used for gene-editing and protein engineering of lymphocytes are desirable. This position will be a key member of our cancer immunotherapy team and will assist in the differentiation of iPSC-derived T and NK cells, in addition to the execution of in vitro and in vivo studies that test Fate Therapeutics' novel cellular therapy products. The selected candidate is also expected to participate in ongoing collaborations with top academic investigators and prominent pharmaceutical partners to develop novel immune-evasion strategies. This is a full-time, bench-level position reporting to a Scientist in Cancer Immunotherapy and is located at the Company's corporate headquarters in San Diego, California.

Responsibilities

- Differentiation and culture of iPSC-derived T and NK cells using defined research protocols
- Lentiviral transduction of iPSC-derived T and NK cells
- Assessment of T and NK cell phenotype using multi-parameter flow cytometry
- Assessment of iPSC-derived CAR-T function using standard in vitro assays that measure proliferation, cytokine secretion, and target cell killing
- Execution of in vitro and in vivo allogeneic rejection models including MLRs and NK cell cytotoxicity assays
- Support programs at Fate in the areas of tumor immunology and cellular immunotherapies
- Present data to immunology groups and larger program-specific teams

Qualifications

- PhD degree in Immunology, Cell Biology or related fields with 0-2 years postdoctoral experience in Immunology, Cell Biology or related fields preferably in a mid-stage biotech, or pharmaceutical setting or 5 plus years relevant experience with MS / BS degree.
- In-depth experience with multi-parameter flow cytometry
- In-depth experience in mammalian cell culture
- In-depth experience in executing and developing assays for primary human T or NK cells
- Experience with IncuCyte and/or xCELLigence platforms is a plus
- Experience with current molecular biology techniques for editing and engineering of T cells and NK cells is a plus
- Proven ability to coordinate with multiple researchers for scheduling and execution of complex experiments
- Excellent communication and organization skills are essential
- Positive outlook and a team-oriented attitude

**Working Conditions and Physical Requirements**

- Will require working with cells and cell lines of human and/or animal origin
- Will require working with hazardous materials
- 100% on-site work at corporate headquarters in San Diego, CA
- Evening and weekend work as necessary

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and resume to: careers@fatetherapeutics.com and reference job code 413AW.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.